“…Most studies reporting individual results for second-line or subsequent VEGFR TKIs have also reported better results than those achieved in our study ( Table 3 ). 12 , 13 , 14 , 15 , 16 , 24 , 25 , 26 Rini et al., 13 in a phase III, randomized, open-label trial, reported similar results with third-line tivozanib (an ORR of 18% and a PFS of 5.6 months) and poorer results with third-line sorafenib (an ORR of 8% and a PFS of 3.9 months). On the other hand, in a prospective phase II study with axitinib in 40 patients who had received an ICI (mostly nivolumab monotherapy and less frequently the combination of ipilimumab–nivolumab), 18 (45%) achieved an OR—17 of them had partial responses—and a median PFS of 8.8 months 12 ; in a post hoc analysis, the authors did not find an association between previous type of ICI-based therapy and response to axitinib, nor with previous nivolumab monotherapy versus ipilimumab plus nivolumab.…”